| Breakdown | TTM | Dec 2025 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82B | ― | 1.82B | 2.11B | 2.19B | 2.39B |
| Gross Profit | 549.00M | ― | 549.00M | 618.00M | 668.00M | 830.00M |
| EBITDA | -512.00M | ― | -509.00M | 303.00M | 457.00M | 509.00M |
| Net Income | -844.00M | ― | -845.00M | 169.00M | 178.00M | 927.00M |
Balance Sheet | ||||||
| Total Assets | 4.62B | ― | 4.61B | 5.64B | 5.94B | 6.21B |
| Cash, Cash Equivalents and Short-Term Investments | 207.00M | ― | 215.00M | 300.00M | 417.00M | 646.00M |
| Total Debt | 1.49B | ― | 1.49B | 1.47B | 1.46B | 1.38B |
| Total Liabilities | 2.73B | ― | 2.71B | 2.78B | 2.84B | 2.99B |
| Stockholders Equity | 1.89B | ― | 1.90B | 2.87B | 3.10B | 3.22B |
Cash Flow | ||||||
| Free Cash Flow | 116.00M | ― | -4.00M | 274.00M | 73.00M | -326.00M |
| Operating Cash Flow | 200.00M | ― | 94.00M | 411.00M | 243.00M | -213.00M |
| Investing Cash Flow | -63.00M | ― | -3.00M | -51.00M | -109.00M | 1.56B |
| Financing Cash Flow | -231.00M | ― | -179.00M | -479.00M | -371.00M | -896.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $2.59B | 29.82 | 36.41% | 1.87% | 4.98% | 30.84% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | $2.94B | -3.51 | -34.45% | 2.79% | -13.67% | -608.89% | |
59 Neutral | $2.36B | -35.99 | -38.91% | ― | -13.39% | 88.25% | |
58 Neutral | $2.63B | -301.55 | -0.64% | 1.37% | 0.08% | -107.33% | |
54 Neutral | $2.00B | -1,363.61 | -0.09% | 2.19% | -4.49% | -100.80% | |
49 Neutral | $2.21B | -6.62 | -69.74% | 4.37% | 2.12% | -579.74% |
Ashland Inc. reported its fourth-quarter fiscal 2025 results, showing a sales decline to $478 million, down eight percent from the previous year, primarily due to Portfolio Optimization initiatives. Despite challenging market conditions, Ashland maintained strong margins and delivered consistent revenue and EBITDA, with growth in Personal Care and Life Sciences segments. The company received a $103 million tax refund related to the Nutraceuticals divestiture, strengthening its financial position. Ashland’s strategic focus on cost management and portfolio alignment positions it for future profit growth.
The most recent analyst rating on (ASH) stock is a Hold with a $60.00 price target. To see the full list of analyst forecasts on Ashland stock, see the ASH Stock Forecast page.